FOI 6793 - usage of medicines in secondary care

Please send two datasets and provide answers to the questions in section 3 for your Trust, to inform this analysis:

(1) Drug Patient Level Contract Monitoring (DrPLCM) report

Data fields from the DrPLCM report, as specified in table 1 (below). Please do not send patient IDs or cost data, as I appreciate this would compromise data privacy and commercial sensitivity.

(2) SACT Cancer report

An extract from the chemotherapy ePMA system showing patients treated by drug and diagnosis, as specified in table 2 (below). Please also address the questions in section 3 which aims to give me top level information on the number of patients treated for different types of breast cancer.

Please email your response by reply with the data in .csv format for the two datasets and input your responses for section 3 in the respective boxes.

Appendices – specifications

Please include the following data fields in each of these data extracts. The data fields specified below reflect the specification given in the NHS data dictionary for the respective dataset.

(1) Table 1 - Drug Patient Level Contract Monitoring (DrPLCM) report

Please select all DrPLCM records between **Apr 2022 and Aug 2022** for all hospitals in your NHS Trust.

Name of "Data Element" from NHS Data Model and Dictionary for DrPLCM
FINANCIAL MONTH
FINANCIAL YEAR
ORGANISATION IDENTIFIER (CODE OF PROVIDER)
ORGANISATION IDENTIFIER (CODE OF COMMISSIONER)
ORGANISATION SITE IDENTIFIER (OF TREATMENT)
ACTIVITY TREATMENT FUNCTION CODE
CLINICAL INTERVENTION DATE (DRUG DISPENSED)
THERAPEUTIC INDICATION CODE (SNOMED CT, OR ICD-10, OR TEXT DESCRIPTION)
HIGH-COST TARIFF EXCLUDED DRUG CODE (SNOMED CT DM+D)
DM+D TAXONOMY CODE (HIGH-COST TARIFF EXCLUDED DRUG)
DRUG NAME (HIGH-COST TARIFF EXCLUDED DRUG)
ROUTE OF ADMINISTRATION (SNOMED CT DM+D)
DRUG STRENGTH (HIGH-COST TARIFF EXCLUDED DRUG)
DRUG VOLUME (HIGH-COST TARIFF EXCLUDED DRUG)
DRUG PACK SIZE (HIGH-COST TARIFF EXCLUDED DRUG)
DRUG QUANTITY OR WEIGHT PROPORTION (HIGH-COST TARIFF EXCLUDED DRUG)
UNIT OF MEASUREMENT (SNOMED CT DM+D)
DISPENSING ROUTE (HIGH-COST TARIFF EXCLUDED DRUG)
COMMISSIONED SERVICE CATEGORY CODE
PROVIDER REFERENCE NUMBER
SPECIALISED SERVICE CODE
NATIONAL CANCER DRUGS FORM CODE
CONTRACT MONITORING ADDITIONAL DETAIL (FIRST)
CONTRACT MONITORING ADDITIONAL DESCRIPTION (FIRST)

(2) Table 2 - SACT Cancer report

Please select data records from the chemotherapy ePMA system between **Apr 2022 and Aug 2022**, for all solid tumour or haematological malignancies (ICD-10 primary diagnosis codes = C* or D*).

Data Field from NHS Data Model and Dictionary for SACT
ORGANISATION IDENTIFIER (CODE OF PROVIDER)
ORGANISATION IDENTIFIER (OF SACT THERAPY ADMINISTRATION)
PRIMARY DIAGNOSIS (tumour type)
PRIMARY DIAGNOSIS CODE (SNOMED CT OR ICD-10 3 or 4 digit)
MORPHOLOGY ICD-O
DIAGNOSIS CODE (SNOMED CT)
ADJUNCTIVE THERAPY TYPE
SACT DRUG NAME
SACT DRUG (SNOMED CT DM+D)
SACT ACTUAL DOSE
SACT UNIT OF MEASUREMENT
SACT THERAPY ADMINISTRATION DATE
SACT DRUG TREATMENT INTENT
CLINICAL TRIAL INDICATOR
TNM STAGE
DRUG REGIMEN DESCRIPTION
NUMBER OF PLANNED CYCLES
NUMBER OF PATIENT RECORDS

(3) Breast Cancer information

I am interested to know the total number of patients with **breast cancer** treated with medicines between **Apr 2022 and Aug 2022**. When responding to the questions below please count all patients treated with chemotherapies, biological agents, hormonal therapies etc., but exclude patients treated with surgery only and/or radiotherapy only.

1. How many patients with breast cancer were treated in total? | 56 |

2. How many patients with breast cancer were treated at the following stages?

   - Early breast cancer (stages I or II) | 28 |
   - Locally advanced breast cancer (stage III) | *<5 |
   - Metastatic breast cancer (stage IV) | *<5 |

3. How many patients with breast cancer were treated in the following categories of tumour characteristics and staging?
   Information not held

Early breast cancer	Neoadjuvant	HR+ve (*ER+ve &/or PR+ve*)	
Early breast cancer	Adjuvant	HR+ve (*ER+ve &/or PR+ve*)	
Early breast cancer	Neoadjuvant	HR+ve, HER2+ve	
Early breast cancer	Adjuvant	HR+ve, HER2+ve	
Early breast cancer	Neoadjuvant	HR+ve, HER2-ve	
Early breast cancer	Adjuvant	HR+ve, HER2-ve	
Early breast cancer	Neoadjuvant	HR+ve, HER2-ve, node positive	

• Early breast cancer	Adjuvant	HR+ve, HER2-ve, node positive	
• Early breast cancer	Neoadjuvant	HER2+ve, node positive	
• Early breast cancer	Adjuvant	HER2+ve, node positive	
• Early breast cancer	Neoadjuvant	BRCA1/2 germline mutation positive	
• Early breast cancer	Adjuvant	BRCA1/2 germline mutation positive	
• Early breast cancer	Neoadjuvant	Triple negative	
• Early breast cancer	Adjuvant	Triple negative	
• Early breast cancer	All	PIK3CA mutation	
• Locally advanced	All	HR+ve (*ER+ve &/or PR+ve*)	
• Locally advanced	All	HER2+ve	
• Locally advanced	All	HR+ve, HER2-ve	
• Locally advanced	All	BRCA1/2 germline mutation positive	
• Locally advanced	All	Triple negative, PD-L1 positive	
• Locally advanced	All	Triple negative, PD-L1 negative	
• Locally advanced	All	PIK3CA mutation	
• Metastatic	All	HR+ve (*ER+ve &/or PR+ve*)	
• Metastatic	All	HER2+ve	
• Metastatic	All	HR+ve, HER2-ve	
• Metastatic	All	BRCA1/2 germline mutation positive	
• Metastatic	All	Triple negative, PD-L1 positive	
• Metastatic	All	Triple negative, PD-L1 negative	
• Metastatic	All	PIK3CA mutation	

Definitions

HER2 = human epidermal growth factor 2 protein;

HR+ve = hormone receptor positive (oestrogen receptor positive, ER+ve, progesterone receptor positive, PR+ve, or both ER+ve and PR+ve);

Triple negative = HER2-ve and HR-ve (ER-ve and PR-ve)

BRCA = breast cancer gene;

PD-L1 = programmed death-1 ligand;

PIK3CA = Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha